X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1461) 1461
Publication (74) 74
Book Review (20) 20
Newsletter (7) 7
Book Chapter (5) 5
Newspaper Article (5) 5
Magazine Article (3) 3
Conference Proceeding (1) 1
Dissertation (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
valsartan (1305) 1305
humans (1097) 1097
male (738) 738
index medicus (686) 686
female (662) 662
valine - analogs & derivatives (657) 657
middle aged (598) 598
hypertension - drug therapy (594) 594
hypertension (554) 554
tetrazoles - therapeutic use (542) 542
aged (473) 473
antihypertensive agents - therapeutic use (424) 424
valine - therapeutic use (421) 421
treatment outcome (388) 388
blood pressure - drug effects (376) 376
pharmacology & pharmacy (366) 366
tetrazoles - adverse effects (347) 347
cardiac & cardiovascular systems (312) 312
antihypertensive agents - adverse effects (307) 307
drug therapy, combination (304) 304
adult (302) 302
angiotensin ii type 1 receptor blockers - therapeutic use (284) 284
tetrazoles - administration & dosage (283) 283
heart failure (270) 270
peripheral vascular disease (262) 262
double-blind method (256) 256
valine - adverse effects (256) 256
antihypertensive agents - administration & dosage (246) 246
mortality (238) 238
hypertension - physiopathology (219) 219
blood-pressure (209) 209
blood pressure (208) 208
valine - administration & dosage (206) 206
drug therapy (203) 203
amlodipine (200) 200
angiotensin (195) 195
heart failure - drug therapy (183) 183
angiotensin-converting enzyme inhibitors - therapeutic use (182) 182
tetrazoles - pharmacology (177) 177
losartan (173) 173
double-blind (163) 163
angiotensin ii type 1 receptor blockers - adverse effects (162) 162
efficacy (161) 161
dose-response relationship, drug (154) 154
medicine, general & internal (151) 151
hydrochlorothiazide (150) 150
risk factors (144) 144
drug combinations (143) 143
internal medicine (141) 141
enalapril (137) 137
prospective studies (137) 137
valine - pharmacology (135) 135
heart-failure (133) 133
therapy (131) 131
angiotensin receptor antagonists (127) 127
medicine & public health (127) 127
trial (123) 123
randomized controlled trials as topic (122) 122
animals (118) 118
antihypertensive agents - pharmacology (117) 117
dosage and administration (116) 116
analysis (114) 114
prevention (114) 114
angiotensin ii type 1 receptor blockers - administration & dosage (113) 113
research (113) 113
amlodipine - therapeutic use (112) 112
cardiology (111) 111
hypertension - complications (110) 110
management (109) 109
time factors (105) 105
safety (104) 104
aged, 80 and over (103) 103
amlodipine - administration & dosage (103) 103
follow-up studies (103) 103
care and treatment (102) 102
morbidity (101) 101
combination therapy (100) 100
hydrochlorothiazide - therapeutic use (96) 96
medicine, research & experimental (95) 95
pharmacology/toxicology (95) 95
amlodipine - adverse effects (92) 92
clinical trials (90) 90
hydrochlorothiazide - administration & dosage (90) 90
randomized-trial (90) 90
combination (88) 88
renin-angiotensin system - drug effects (88) 88
tolerability (87) 87
diuretics (86) 86
sacubitril/valsartan (86) 86
angiotensin receptor blocker (85) 85
benzimidazoles - therapeutic use (85) 85
cardiovascular (85) 85
risk (84) 84
telmisartan (84) 84
abridged index medicus (82) 82
candesartan (82) 82
outcomes (81) 81
heart failure - physiopathology (80) 80
hydrochlorothiazide - adverse effects (80) 80
diabetes (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1396) 1396
German (29) 29
Russian (15) 15
Spanish (15) 15
Japanese (7) 7
Chinese (6) 6
French (5) 5
Italian (2) 2
Danish (1) 1
Dutch (1) 1
Hungarian (1) 1
Indonesian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 993 - 1004
Journal Article
EUROPEAN HEART JOURNAL, ISSN 0195-668X, 04/2017, Volume 38, Issue 15, pp. 1132 - 1143
Background Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse,... 
Heart failure | TRIAL | AT1-receptor | NEPRILYSIN INHIBITION | CARDIAC & CARDIOVASCULAR SYSTEMS | Angiotensin | Neprilysin | Blood pressure | ENALAPRIL | Valsartan - administration & dosage | Humans | Aminobutyrates - adverse effects | Male | Death, Sudden, Cardiac - etiology | Enalapril - adverse effects | Dose-Response Relationship, Drug | Hypotension - mortality | Tetrazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Blood Pressure - drug effects | Aminobutyrates - administration & dosage | Drug Therapy, Combination | Enalapril - administration & dosage | Heart Failure - mortality | Drug Administration Schedule | Stroke Volume - physiology | Valsartan - adverse effects | Treatment Outcome | Hospitalization | Hypotension - chemically induced | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Heart Failure - drug therapy | Neprilysin - antagonists & inhibitors | Aged | Tetrazoles - adverse effects | Chronic Disease | Angiotensin Receptor Antagonists - administration & dosage | Angiotensin Receptor Antagonists - adverse effects | Clinical Research | Editor's Choice | Kardiologi | Cardiac and Cardiovascular Systems | enalapril heart failure | chronic hypotension systolic blood pressure heart failure blood pressure cardiovascular system safety ejection fraction cardiovascular death sacubitril / valsartan
Journal Article
JACC: Heart Failure, ISSN 2213-1779, 07/2017, Volume 5, Issue 7, pp. 471 - 482
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10017, pp. 435 - 443
Journal Article
Circulation, ISSN 0009-7322, 06/2016, Volume 133, Issue 23, pp. 2254 - 2262
BACKGROUND—Many episodes of worsening of heart failure (HF) are treated by increasing oral therapy or temporary intravenous treatment in the community or... 
mortality | heart failure | hospitalization | neprilysin | emergency service, hospital | sacubitril/valsartan | NEPRILYSIN INHIBITION | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK | CARE | SUBSEQUENT MORTALITY | HOSPITAL READMISSION | EMERGENCY-DEPARTMENT | THERAPY | PERIPHERAL VASCULAR DISEASE | OUTCOMES | ENALAPRIL | INPATIENT | Angiotensin II Type 1 Receptor Blockers - adverse effects | Prospective Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Male | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Heart Failure - therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Endpoint Determination | Protease Inhibitors - adverse effects | Female | Heart Failure - diagnosis | Protease Inhibitors - therapeutic use | Heart Failure - mortality | Double-Blind Method | Risk Assessment | Risk Factors | Treatment Outcome | Hospitalization | Neprilysin - metabolism | Ambulatory Care | Disease Progression | Neprilysin - antagonists & inhibitors | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Research Design | Heart failure | Care and treatment | Emergency service | Receptors | Hospitals | Analysis | Angiotensin | Comparative analysis | ACE inhibitors | Health aspects | Risk factors | hospital readmission | emergency-department | enalapril | inpatient | therapy | subsequent mortality | Kardiologi | Cardiac and Cardiovascular Systems | neprilysin inhibition | Cardiovascular System & Cardiology | outcomes | emergency service | risk | hospital | care
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9583, pp. 221 - 229
Journal Article
Hypertension, ISSN 0194-911X, 02/2008, Volume 51, Issue 2, pp. 393 - 398
Journal Article
The Lancet, ISSN 0140-6736, 06/2004, Volume 363, Issue 9426, pp. 2022 - 2031
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan... 
CALCIUM-CHANNEL BLOCKER | LIPID-LOWERING TREATMENT | RECEPTOR BLOCKER | MEDICINE, GENERAL & INTERNAL | ISOLATED SYSTOLIC HYPERTENSION | CONVERTING-ENZYME-INHIBITOR | DOUBLE-BLIND | ANGIOTENSIN-II | ELECTROCARDIOGRAPHIC IDENTIFICATION | CORONARY-ARTERY-DISEASE | BLOOD-PRESSURE | Calcium Channel Blockers - adverse effects | Valsartan | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Male | Sodium Chloride Symporter Inhibitors - therapeutic use | Angiotensin II Type 1 Receptor Blockers | Endpoint Determination | Diuretics | Female | Blood Pressure - drug effects | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Amlodipine - adverse effects | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Amlodipine - therapeutic use | Antihypertensive Agents - adverse effects | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Tetrazoles - adverse effects | Valine - adverse effects | Hydrochlorothiazide - therapeutic use | Hypertension | Medical research | Side effects | Drug therapy | Drugs | Heart attacks | Heart surgery | Angioplasty | Risk | Cardiovascular disease | Blood | Randomization | Measurement techniques | Blood pressure | Heart diseases | Age | Heart failure | Edema | Stroke | Mortality | Medical treatment | Health risks | Angina pectoris | Patients | Coronary artery disease | Morbidity | Hypotheses | Coronary vessels | Diabetes | Cardiovascular diseases | Health risk assessment | Mercury | ACE inhibitors
Journal Article